Belgian healthech startup Minze Health has raised €3.9 million in a recent funding round. The company plans to use the capital to fuel further growth, including the commencement of clinical studies in Europe and the US, running in tandem with the development of go-to-market strategies in both the B2B and consumer health sectors.
Focusing on the treatment of the 2.3 billion individuals who suffer lower urinary tract symptoms, the startup’s digital health and remote patient monitoring (RPM) solutions are already in use by some 300 hospitals, urology practices, and pelvic floor rehabilitation centers worldwide.
As incontinence and other urological complaints are often discussed behind closed doors if at all, a large portion of individuals are often treated too late or not at all. The goal at Minze Health is to break this taboo by providing simple and accessible screening methods for patients and improved and easy-to-use diagnostic tools for the clinician.
Minze’s medical devices and digital health solutions are CE-marked and FDA listed, and are available in over 20 countries and regions including Benelux, Germany, UK, France, Spain, Australia, Japan, Saudi Arabia, and the US.
On the investment, PMV senior investment manager Tine Bekaert comments, “Minze Health’s solutions to often unspoken social problems, represent enormous international potential. We are convinced that thanks to a unique combination of medical products with low-threshold and comprehensive software diagnostics, patients around the world facing urology problems will find their way to this accessible form of home diagnostics.”